Comparison of the safety information on drug labels in three developed countries: The USA, UK and Canada

Abedtash, 2015, An interactive user interface for drug labeling to improve readability and decision-making, AMIA Annu. Symp. Proc., 2015, 278 Arnold, 2010, Exploring differences in drug doses between Japan and Western countries, Clin. Pharmacol. Ther., 87, 714, 10.1038/clpt.2010.31 Beach, 1998, Black box warnings in prescription drug labeling: results of a survey of 206 drugs, Food Drug Law J., 53, 403 Best Practice Guidance On The Labelling [WWW Document], 2016. <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/474366/Best_practice_guidance_labelling_and_packaging_of_medicines.pdf> (accessed 4.25.16). Blank, 2015, New drug labels for pregnancy lauded, Contemp. Pediatr., 32, 10 Cheng PharmD, 2014, Prevalence and therapeutic classifications of FDA-approved prescription drugs with boxed warnings, Ther. Innov. Regul. Sci., 48, 165, 10.1177/2168479013496091 Cook, 2009, Risk management policy and black-box warnings, Drug Saf., 32, 1057, 10.2165/11316670-000000000-00000 Cooper, 1986, Drug labeling and products liability: the role of the Food and Drug Administration, Food Drug Cosm. LJ, 41, 233 DailyMed [WWW Document], 2016. <http://dailymed.nlm.nih.gov/dailymed/> (accessed 3.29.16). Davis, 2006, Literacy and misunderstanding prescription drug labels, Ann. Int. Med., 145, 887, 10.7326/0003-4819-145-12-200612190-00144 Duke, 2011, A quantitative analysis of adverse events and “overwarning” in drug labeling, Arch. Int. Med., 171, 941, 10.1001/archinternmed.2011.182 electronics Medical Compendium [WWW Document], 2016. <https://www.medicines.org.uk/emc/> (accessed 3.29.16). Guidance Document [WWW Document], 2016. <http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/label_guide_ld-eng.php> (accessed 4.25.16). Health Canada, 2016. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp> (accessed 3.29.16). King, 2016, Developing consumer-centered, nonprescription drug labeling, Am. J. Prev. Med., 40, 593, 10.1016/j.amepre.2011.02.016 Kircik, 2016, United States Food and Drug Administration Product Label Changes, J. Clin. Aesthet. Dermatol., 9, 39 Labeling [WWW Document], 2016. <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065010.htm> (accessed 4.25.16). Malinowski, 2008, Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan, J. Clin. Pharmacol., 48, 900, 10.1177/0091270008319794 Raymond, 2000, Drug labeling revisions—guaranteed to fail?, JAMA, 284, 3047, 10.1001/jama.284.23.3047 Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products. Final Rule., 2006. Fed. Regist. 71, pp. 3921–3997. Shimazawa, 2013, Safety information in drug labeling: a comparison of the USA, the UK, and Japan, Pharmacoepidemiol. Drug Saf., 22, 306, 10.1002/pds.3408 Shimazawa, 2013, Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan, J. Clin. Pharm. Ther., 38, 468, 10.1111/jcpt.12089 Thalidomide Drug Label in UK [WWW Document], 2016. <https://www.medicines.org.uk/emc/medicine/21005> (accessed 4.25.16).